FORM 5
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
[ ] Form 3 Holdings Reported
[ ] Form 4 Transactions Reported		 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
ANNUAL STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
 OMB APPROVAL
OMB Number: 3235-0362
Estimated average burden
hours per response... 1.0
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                       
1. Name and Address of Reporting Person * BOYNTON ALTON L 2. Issuer Name and Ticker or Trading SymbolNORTHWEST BIOTHERAPEUTICS INC [NWBO] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable)_____ Director                    _____ 10% Owner
__X__ Officer (give title below)    _____ Other (specify below)
CHIEF SCIENTIFIC OFFICER
(Last)          (First)          (Middle)
4800 MONGTGOMERY #800		 3. Statement for Issuer's Fiscal Year Ended (MM/DD/YYYY)
12/31/2022 
(Street)
BETHSDA, MD 20814
(City)        (State)        (Zip)
 4. If Amendment, Date Original Filed(MM/DD/YYYY)
 
 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form Filed by One Reporting Person
___ Form Filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)		 2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)		 4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)		 5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)		 6. Ownership Form: Direct (D) or Indirect (I)
(Instr. 4)		 7. Nature of Indirect Beneficial Ownership
(Instr. 4)
Amount (A) or (D) Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)		 2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8)		 5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)		 6. Date Exercisable and Expiration Date
(MM/DD/YYYY)		 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)		 8. Price of Derivative Security
(Instr. 5)		 9. Number of Derivative Securities Beneficially Owned at End of Issuer's Fiscal Year
(Instr. 4)		 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4)		 11. Nature of Indirect Beneficial Ownership
(Instr. 4)
(A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
COMMON STOCK OPTIONS  $0.23  5/26/2022    G (1)    4900000   5/28/2018  5/28/2028  COMMON STOCK PAR VALUE $0.001  4900000  $0  9761256  D   
COMMON STOCK OPTIONS  $0.35  7/27/2022    G (1)    3000000   7/2/2020  12/1/2030  COMMON STOCK PAR VALUE $0.001  3000000  $0  9761256  D   
COMMON STOCK OPTIONS  $0.35  12/6/2022    G (1)    4500000   7/2/2020  12/1/2030  COMMON STOCK PAR VALUE $0.001  4500000  $0  9761256  D   
COMMON STOCK OPTIONS  $0.35  12/6/2022    G (1)    4500000   7/2/2020  12/1/2030  COMMON STOCK PAR VALUE $0.001  4500000  $0  9761256  D   

Explanation of Responses:
(1)  GIFTS FROM DR. BOYNTON FOR ESTATE PLANNING PURPOSES.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
BOYNTON ALTON L
4800 MONGTGOMERY #800
BETHSDA, MD 20814

CHIEF SCIENTIFIC OFFICER

Signatures
/s/ Dr. Alton L. Boynton 2/7/2023
**Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Northwest Biotherapeutics (QB) (USOTC:NWBO)
Historical Stock Chart
From Feb 2023 to Mar 2023 Click Here for more Northwest Biotherapeutics (QB) Charts.
Northwest Biotherapeutics (QB) (USOTC:NWBO)
Historical Stock Chart
From Mar 2022 to Mar 2023 Click Here for more Northwest Biotherapeutics (QB) Charts.